Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling

Journal of Nephrology

Volumn 25, Issue 4, 2012, Pages 577-581

  Pacini, Stefania ^a   Morucci, Gabriele ^a   Punzi, Tiziana ^a   Gulisano, Massimo ^a   Ruggiero, Marco ^a   Amato, Marcello ^b   Aterini, Stefano ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b MISERICORDIA E DOLCE HOSPITAL   (Italy)

Author keywords

Angiogenesis; Mononuclear cells; Parical citol; Proliferation

Indexed keywords

CYCLIC AMP; GC MACROPHAGE ACTIVATING FACTOR; MACROPHAGE ACTIVATING FACTOR; PARICALCITOL; PROSTAGLANDIN E1; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SUSPENSION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DNA POLYMORPHISM; GENE INTERACTION; GENOTYPE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MACROPHAGE ACTIVATION; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RECEPTOR GENE; SIGNAL TRANSDUCTION; VITAMIN D RECEPTOR GENE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CYCLIC GMP; ERGOCALCIFEROLS; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGE-ACTIVATING FACTORS; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; VITAMIN D-BINDING PROTEIN;

EID: 84863890011     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000035     Document Type: Article

References (30)

1. Chishimba L, Thickett DR, Stockley RA, Wood AM. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax. 2010;65(5):456-462.
2. Yamamoto N, Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res. 1997; 57(11):2187-2192.
3. Ruggiero M, Pacini S. The vitamin D axis in chronic kidney disease: state of the art and future perspectives. Eur Nephrol. 2011;5:15-19.
4. Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res. 2004;19(3):419-428.
5. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta. 2006;371(1-2):1-12.
6. Halsall JA, Osborne JE, Pringle JH, Hutchinson PE. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Phar-macogenet Genomics. 2005;15(5):349-355.
7. Alvarez-Hernandez D, Naves-Diaz M, Gomez-Alonso C, Coto E, Cannata-Andia JB. Tissue-specific effect of VDR gene polymorphisms on the response to calcitriol. J Nephrol. 2008; 21(6):843-849.
8. Yamamoto N, Ushijima N, Koga Y. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). J Med Virol. 2009;81(1):16-26.
9. Futrakul N, Butthep P, Laohareungpanya N, Chaisuriya P, Ratanabanangkoon K. A defective angiogenesis in chronic kidney disease. Ren Fail. 2008;30(2):215-217.
10. Chung I, Han G, Seshadri M, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009;69(3):967-975.
11. Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M. Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay. Cancer Immunol Immunother. 2010 Dec 14. [Epub ahead of print].
12. Nagasawa H, Uto Y, Sasaki H, et al. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res. 2005;25(6A):3689-3695.
13. Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst. 2002;94(17):1311-1319.
14. Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of angio-genesis by vitamin D-binding protein: characterization of an-ti-endothelial activity of DBP-maf. Angiogenesis. 2005;8(4): 349-360.
15. Sardenberg C, Suassuna P, Watanabe R, et al. Balance between cytokine production by peripheral blood mononuclear cells and reactive oxygen species production by monocytes in patients with chronic kidney disease. Ren Fail. 2004;26(6): 673-681.
16. Amato M, Pacini S, Aterini S, Punzi T, Gulisano M, Ruggiero M. Iron indices and vitamin D receptor polymorphisms in hemodi-alysis patients. Adv Chronic Kidney Dis. 2008;15(2):186-190.
17. Ribatti D, Nico B, Vacca A, Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc. 2006;1(1):85-91.
18. Giles FJ. The emerging role of angiogenesis inhibitors in he-matologic malignancies. Oncology (Williston Park). 2002;16(5) (Suppl 4):23-29.
19. Takahashi HK, Liu K, Wake H, et al. Prostaglandin E2 inhibits advanced glycation end product-induced adhesion molecule expression, cytokine production, and lymphocyte proliferation in human peripheral blood mononuclear cells. J Pharmacol Exp Ther. 2009;331(2):656-670.
20. Patel TV, Singh AK. Role of vitamin D in chronic kidney disease. Semin Nephrol. 2009;29(2):113-121.
21. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int. 2011;79(7):702-707.
22. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int. 2010;78(2):146-151.
23. Ichinose K, Maeshima Y, Yamamoto Y, et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 2005; 54(10):2891-2903.
24. Tsopanoglou NE, Haralabopoulos GC, Maragoudakis ME. Opposing effects on modulation of angiogenesis by protein kinase C and cAMP-mediated pathways. J Vasc Res. 1994;31(4):195-204.
25. Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30(7):1170-1180.
26. Ta n X, He W, Liu Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropa-thy. Kidney Int. 2009;76(12):1248-1257.
27. Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, Gc-MAF. Cancer Immunol Immunother. 2008;57(7):1007-1016.
28. Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immu-notherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (Gc-MAF). Int J Cancer. 2008;122(2):461-467.
29. Yamamoto N, Suyama H, Yamamoto N. Immunotherapy for prostate cancer with Gc protein-derived macrophage activating factor, GcMAF. Transl Oncol. 2008;1(2):65-72.
30. Hayon T, Dvilansky A, Shpilberg O, Nathan I. Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk Lymphoma. 2003;44(11): 1957-1962.